This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
Tephrosia purpurea contains bioactive compounds including rutin, tephrosin, flavonoids, and tannins that contribute to its medicinal effects. The flavonoids and rutin provide hepatoprotective activity through antioxidant mechanisms, helping protect liver cells from oxidative stress. Tephrosin demonstrates anti-inflammatory properties, while the herb's bitter principles stimulate digestive secretions. Rotenone, another constituent, has insecticidal properties but raises safety concerns at higher doses. Evidence level: C (preclinical studies support these mechanisms, though human trials remain limited).
What are the drug interactions of Tephrosia purpurea?
Tephrosia purpurea may interact with medications metabolized by the liver due to its effects on hepatic function. The presence of rotenone and other bioactive compounds could potentially alter the metabolism of drugs processed through hepatic pathways. Patients taking hepatotoxic medications, immunosuppressants, or drugs requiring precise therapeutic dosing should exercise caution. Those on diabetes or blood pressure medications should monitor for additive effects. Always consult a healthcare provider before combining with prescription medications. Evidence level: C.
What is the recommended dosage for Tephrosia purpurea?
Traditional Ayurvedic practice recommends Tephrosia purpurea root powder at 3-5 grams taken twice daily, or as a root decoction prepared from dried roots. The herb is typically consumed with water or honey. Standardized extracts may have different dosing requirements based on concentration. Due to rotenone content and potential dose-dependent liver effects, users should adhere strictly to recommended amounts and avoid prolonged use without medical supervision. Evidence level: Traditional/C.
Is Tephrosia purpurea safe during pregnancy and breastfeeding?
Tephrosia purpurea is considered unsafe during pregnancy and should be strictly avoided. The herb contains rotenone, a compound with potential toxicity, and has traditional emmenagogue properties that may stimulate uterine contractions, posing a risk of miscarriage. There is insufficient safety data for breastfeeding women, so nursing mothers should also avoid this herb. Women who are pregnant, planning pregnancy, or breastfeeding should consult a qualified healthcare provider before using any herbal supplements.
What is Tephrosia purpurea used for in Ayurvedic medicine?
Tephrosia purpurea, known as 'Sharapunkha' in Ayurveda, is traditionally used for liver disorders, spleen enlargement, respiratory conditions including asthma, skin diseases, and jaundice. The root is the primary medicinal part, valued for its bitter and astringent properties. In Ayurvedic classification, it functions as a liver tonic and blood purifier. Modern preclinical research supports hepatoprotective and anti-inflammatory effects, though robust human clinical trials remain limited. Evidence level: C/Traditional use.
What are the side effects of Tephrosia purpurea?
Common side effects of Tephrosia purpurea include gastrointestinal upset such as nausea, vomiting, or diarrhea, particularly when taken in excessive doses or on an empty stomach. More concerning is the potential for liver toxicity with prolonged or high-dose use due to rotenone content. Individuals with pre-existing liver disease should avoid this herb entirely. Users should discontinue immediately if experiencing jaundice, abdominal pain, or unusual fatigue, and seek medical attention. Evidence level: C/Traditional.
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Tephrosia purpurea, also known as 'Sarapunkha', is a perennial plant of the Fabaceae family used in Ayurvedic medicine for its wound healing and hepatoprotective properties [PMID:24484589, PMID:32147928].
Background
Tephrosia purpurea (L.) Pers., commonly referred to as Wild Indigo or Purple Tephrosia, is a perennial plant found throughout the Indian subcontinent [PMID:22557415, PMID:24484589].
Traditional uses
In Ayurvedic medicine, it is used to treat splenomegaly, cirrhosis, cough, cold, abdominal swelling, impotency, asthma, dyspepsia, hemorrhoids, syphilis, gonorrhea, rheumatism, and enlargement of the kidney and spleen [PMID:24484589, PMID:32147928]. It is also used as an antidote and for treating jaundice and urinary disorders [PMID:24484589, PMID:28479720].
Active compounds
Phytochemicals include flavonoids (rutin, (+)-tephrorin A and B, (+)-tephrosone, glabratephrin, demeapollinin, tephroapollin G), chalcones (pongamol, (+)-tephropurpurin), isoflavones, and others such as $\beta$-sitosterol, lupeol, semiglabrin, purpurin, and purpurenone [PMID:24484589, PMID:32147928, PMID:32840388, PMID:32878453, PMID:25116833].
Mechanism of action
The plant exhibits acetylcholinesterase inhibitory action [PMID:32147928, PMID:32878453]. It demonstrates aldose reductase inhibitory activity in the polyol pathway to prevent diabetic cataracts [PMID:27372406]. Glabratephrin inhibits P-glycoprotein (Pgp) to increase doxorubicin accumulation in breast cancer cells [PMID:34785319]. In skin cells, it stimulates well-being hormones while reducing cortisol release [PMID:31232507].
Clinical evidence
Evidence BSkin Homeostasis
A clinical study of 21 women in polluted environments showed the extract significantly reduced cortisol release and improved global skin [PMID:31232507]
Evidence DDiabetic Cataract
Alcoholic and flavonoid fractions prevented cataract formation in STZ-induced diabetic rats by inhibiting aldose reductase [PMID:27372406]
Evidence DHepatotoxicity
Hydro-alcoholic extract (500 mg/kg) reduced serum ALT, AST, and ALP activity and decreased liver necrosis and inflammation in arsenic-induced toxicity rats [PMID:24741193]
Evidence DNephrotoxicity
Extract (500 mg/kg) significantly reduced blood urea nitrogen and plasma creatinine in arsenic-induced toxicity rats [PMID:24748739]
Evidence DHepatocellular Carcinoma
Leaf and root extracts inhibited HepG2 cell growth via induction of caspase-3 and apoptosis [PMID:28479720]
Evidence DGastric Ulcers
Drug interactions
Glabratephrin increases the accumulation and cytotoxicity of doxorubicin by inhibiting P-glycoprotein [PMID:34785319].
Evidence summary
Evidence is primarily based on in vitro cell lines and in vivo animal models (Level D), with one small clinical study on skin health (Level B) and several comprehensive reviews (Level C).
PubMed sources
1.PMID: 32840388 (2022) — A chalcone (Pongamol) and phytoconstituents of Tephrosia purpurea. · Natural product research
2.PMID: 24484589 (2014) — Ethnopharmacology, phytochemistry and pharmacology of Tephrosia purpurea. · Chinese journal of natural medicines
3.PMID: 21808544 (2010) — Chemical constituents of Tephrosia purpurea. · Pharmacognosy research
4.PMID: 32147928 (2020) — A comprehensive review on ethnomedicine, phytochemistry, pharmacology, and toxicity of Tephrosia purpurea (L.) Pers. · Phytotherapy research : PTR
5.PMID: 32878453 (2021) — New prenylated flavonoid and neuroprotective compounds from Tephrosia purpurea subsp. dunensis. · Natural product research
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
Combination of T. purpurea and Bacopa monnieri ethanolic leaf extracts showed synergistic anti-ulcer activity in rats [PMID:39043 la71]
Evidence DBronchospasm
Total extract showed potent ex-vivo bronchodilator effects in Guinea pig tracheal muscles [PMID:38435847]
6.
PMID: 35983619 (2023) — Repurposing small molecules of Tephrosia purpurea against SARS-CoV-2 main protease. · Journal of biomolecular structure & dynamics
7.PMID: 22557415 (2010) — Pharmacognostical Standardization of Tephrosia purpurea Pers Root. · Ancient science of life
8.PMID: 28479720 (2017) — In vitro Anti-Proliferative Effect of Tephrosia purpurea on Human Hepatocellular Carcinoma Cells. · Pharmacognosy magazine
9.PMID: 10814365 (2000) — Absolute configuration of novel bioactive flavonoids from Tephrosia purpurea. · Organic letters
10.PMID: 27372406 (2016) — Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
11.PMID: 25848963 (2016) — Preventive Effect of Tephrosia purpurea on Selenite-Induced Experimental Cataract. · Current eye research
12.PMID: 31232507 (2020) — Well-aging: A new strategy for skin homeostasis under multi-stressed conditions. · Journal of cosmetic dermatology
13.PMID: 11243714 (2001) — Tephrosia purpurea alleviates phorbol ester-induced tumor promotion response in murine skin. · Pharmacological research
14.PMID: 38435847 (2024) — New flavonoids with multiple bronchodilator activity pathways from Tephrosia purpurea L. (Pers.) growing in Saudi Arabia. · Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
15.PMID: 28255311 (2017) — In vitro antioxidant and cytotoxic potential of different parts of Tephrosia purpurea. · Research in pharmaceutical sciences
16.PMID: 37175349 (2023) — Phytochemical Analysis and Profiling of Antioxidants and Anticancer Compounds from Tephrosia purpurea (L.) subsp. apollinea Family Fabaceae. · Molecules (Basel, Switzerland)
17.PMID: 33383117 (2021) — Deciphering the multi-scale mechanisms of Tephrosia purpurea against polycystic ovarian syndrome (PCOS) and its major psychiatric comorbidities: Studies from network pharmacological perspective. · Gene
18.PMID: 27761428 (2016) — Effects of flavonoids from Martynia annua and Tephrosia purpurea on cutaneous wound healing. · Avicenna journal of phytomedicine
20.PMID: 26798165 (2015) — Effect of Aqueous Extract of Tephrosia purpurea on Cardiovascular Complications and Cataract Associated with Streptozotocin-induced Diabetes in Rats. · Indian journal of pharmaceutical sciences
21.PMID: 34522638 (2021) — Evaluation of pancreatic regeneration activity of Tephrosia purpurea leaves in rats with streptozotocin-induced diabetes. · Journal of traditional and complementary medicine
22.PMID: 39043471 (2024) — Evaluation of Synergistic Activity of Ethanolic Leaf Extracts of Tephrosia Purpurea and Bacopa Monnieri in Ulcer Induced Rats. · Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
23.PMID: 26839503 (2015) — Phylogenetic Diversity and Antifungal Activity of Endophytic Fungi Associated with Tephrosia purpurea. · Mycobiology
24.PMID: 25116833 (2014) — A new 1,2-ethanedione benzofurane derivative from Tephrosia purpurea. · Natural product research
25.PMID: 24741193 (2014) — Hepatoprotective activity of Tephrosia purpurea against arsenic induced toxicity in rats. · Indian journal of pharmacology
26.PMID: 24748739 (2014) — Ameliorative Effect of Tephrosia Purpurea in Arsenic-induced Nephrotoxicity in Rats. · Toxicology international
27.PMID: 34785319 (2022) — Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. · Pharmacological research